For US Healthcare Professionals

Contemplate bone damage in patients with axSpA

Pathogenic processes leading to bone damage

Bone Damage in axSpA

In axSpA, the inflammatory processes and new bone formation take place in the entheses, axial skeleton, and peripheral joints via the cytokine pathways, which are only just starting to be understood.2 Data suggests that bone erosion and new bone formation in axSpA may occur simultaneously at different anatomical sites, with IL-17 playing a complex role in these immune-mediated processes.1


The importance of staying curious in the search for a cure

In this video, Prof. Iain McInnes challenges rheumatologists to stay curious during this exciting time in the study of immune-mediated inflammatory diseases.

Addressing bone changes in axSpA

The underlying processes leading to bone damage in axSpA need to be understood and addressed in order to improve clinical outcomes for patients. The loss of existing bone and new bone formation are highly relevant to overall burden of disease, including clinical manifestations, disability, and long-term outcomes, such as spinal fracture.3

In addressing bone pathophysiology, it is important to focus on robust clinical measures of both bone loss in vertebrae and of the drivers of osteoproliferation. This will help achieve the ultimate goal of developing therapeutic approaches to reduce osteitis/erosion, bone turnover and osteoproliferation, and improve long-term skeletal outcomes.3

Explore the underlying pathologic processes leading to bone damage

Gaze upon the Gallery of Cytokines


axSpA manifestations

Explore the clinical manifestations of axSpA and their impact on patients’ quality of life.

Continue axSpA tour Back to: Immune dysregulation


Immune dysregulation

Back to previous

  1. McGonagle DG, McInnes IB, Kirkham BW, et al. The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. Ann Rheum Dis. 2019;78:1167–1178
  2. Groen SS, Sinkeviciute D, Bay-Jensen AC, et al. Exploring IL-17 in spondyloarthritis for development of novel treatments and biomarkers. Autoimmun Rev. 2021;20(3):102760. doi:10.1016/j.autrev.2021.102760
  3. Clunie G, Horwood N. Loss and gain of bone in spondyloarthritis: what drives these opposing clinical features? Ther Adv Musculoskelet Dis. 2020;12:1759720X20969260. doi:10.1177/1759720X20969260